124 related articles for article (PubMed ID: 21666497)
21. Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses.
Rudinskiy N; Hawkes JM; Wegmann S; Kuchibhotla KV; Muzikansky A; Betensky RA; Spires-Jones TL; Hyman BT
Acta Neuropathol Commun; 2014 Jun; 2():63. PubMed ID: 24915991
[TBL] [Abstract][Full Text] [Related]
22. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
[TBL] [Abstract][Full Text] [Related]
23. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.
Schwab C; Hosokawa M; McGeer PL
Exp Neurol; 2004 Jul; 188(1):52-64. PubMed ID: 15191802
[TBL] [Abstract][Full Text] [Related]
24. Divergent phosphorylation pattern of tau in P301L tau transgenic mice.
Deters N; Ittner LM; Götz J
Eur J Neurosci; 2008 Jul; 28(1):137-47. PubMed ID: 18662339
[TBL] [Abstract][Full Text] [Related]
25. Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation.
Osinde M; Clavaguera F; May-Nass R; Tolnay M; Dev KK
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):523-31. PubMed ID: 18282162
[TBL] [Abstract][Full Text] [Related]
26. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.
Ishihara T; Zhang B; Higuchi M; Yoshiyama Y; Trojanowski JQ; Lee VM
Am J Pathol; 2001 Feb; 158(2):555-62. PubMed ID: 11159192
[TBL] [Abstract][Full Text] [Related]
27. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Lewis J; Dickson DW; Lin WL; Chisholm L; Corral A; Jones G; Yen SH; Sahara N; Skipper L; Yager D; Eckman C; Hardy J; Hutton M; McGowan E
Science; 2001 Aug; 293(5534):1487-91. PubMed ID: 11520987
[TBL] [Abstract][Full Text] [Related]
28. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.
Mewes A; Franke H; Singer D
PLoS One; 2012; 7(9):e45017. PubMed ID: 22984603
[TBL] [Abstract][Full Text] [Related]
29. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
30. Argyrophilic grains are not always argyrophilic--distinction from neurofibrillary tangles of diffuse neurofibrillary tangles with calcification revealed by comparison between Gallyas and Campbell-Switzer methods.
Uchihara T; Tsuchiya K; Nakamura A; Akiyama H
Acta Neuropathol; 2005 Aug; 110(2):158-64. PubMed ID: 15971055
[TBL] [Abstract][Full Text] [Related]
31. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
[TBL] [Abstract][Full Text] [Related]
32. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.
Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L
Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of mouse model exhibiting neurofibrillary changes].
Takashima A
Rinsho Shinkeigaku; 2001 Dec; 41(12):1111-2. PubMed ID: 12235811
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.
Blanchard J; Wanka L; Tung YC; Cárdenas-Aguayo Mdel C; LaFerla FM; Iqbal K; Grundke-Iqbal I
Acta Neuropathol; 2010 Nov; 120(5):605-21. PubMed ID: 20697724
[TBL] [Abstract][Full Text] [Related]
36. A seeding based cellular assay of tauopathy.
Xu Y; Martini-Stoica H; Zheng H
Mol Neurodegener; 2016 Apr; 11():32. PubMed ID: 27112488
[TBL] [Abstract][Full Text] [Related]
37. 3R tau expression modifies behavior in transgenic mice.
Shiryaev N; Jouroukhin Y; Gozes I
J Neurosci Res; 2010 Sep; 88(12):2727-35. PubMed ID: 20544828
[TBL] [Abstract][Full Text] [Related]
38. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
39. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice.
Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I
Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635
[TBL] [Abstract][Full Text] [Related]
40. Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation.
Schindowski K; Belarbi K; Bretteville A; Ando K; Buée L
Genes Brain Behav; 2008 Feb; 7 Suppl 1(1):92-100. PubMed ID: 18184373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
